Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tapinarof · Vtama, DMVT-505

Small molecule · Agonist of aryl hydrocarbon receptor (AHR) · developed by Organon Llc

Approved FDA, May 2022
OGN Developer
3 Registered trials

What is Tapinarof?

Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist. It acts on the aryl hydrocarbon receptor, a transcription factor, and is used in the treatment of plaque psoriasis and atopic dermatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Vtama, DMVT-505, GSK-2894512, WBI-1001
Drug type
Small molecule
Targets
aryl hydrocarbon receptor (AHR)
Mechanism
Agonist of aryl hydrocarbon receptor (AHR)
Therapy area
Dermatology
Developer
Organon Llc (OGN)
FDA status
Approved as Vtama (May 23, 2022), NDA215272 · FDA label
UNII
84HW7D0V04

✅ FDA-approved uses

From the indications section of the FDA label (version of May 28, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05789576 Phase 4 Psoriasis Completed OGN
NCT05680740 Phase 4 Psoriasis Completed OGN
NCT03983980 Phase 3 Plaque Psoriasis Completed OGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Plaque PsoriasisPsoriasis

More from Organon Llc

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the OGN page.

Follow OGN, the company behind Tapinarof

See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.